New migraine treatment has fewer side effects
Tuesday 25 November 2008
Latest in Health News
Related articles
On Facebook
Life & Style blogs
CC kills more people than cervical cancer; why haven’t we heard about it?
There is a disease whose incidence is rising in the UK and most of the industrialised world. However...
Time for a new approach to alcohol
Ambulances were called and three drunk teenagers were brought to my care. One was so drunk we had to...
London Fashion Week countdown
London Fashion Week is nearly upon us (again) and the invites are fast piling up. Our fashion team w...
A new treatment for migraine that is as effective as existing drugs but with fewer side effects will bring fresh hope to millions of sufferers, scientists said yesterday.
Improved understanding of the mechanism that causes the brain to over-react to stimuli has led to the development of a drug that works in a different way from existing treatments.
Migraine affects an estimated six million people in Britain – 15 per cent of the adult population – and runs in families. It is caused by an "oversensitive" brain which reacts to triggers such as fatigue, hunger, stress or the weather with a throbbing, one-sided headache, often accompanied by nausea and visual disturbances. It affects three times more women than men.
The new drug, called telcagepant, is a rescue treatment that interrupts the sequence of chemical reactions in the brain that cause the migraine at a different point from existing drugs.
A final trial of the drug, published in The Lancet today, showed it reduced pain and was better at preventing the return of the migraine over 24 hours than zolmitriptan, an existing triptan drug. However, the improvement was not statistically significant.
The main advantage of telcagepant was reduced side effects. Triptans can cause a tight chest and throat, dizziness, numbness of skin and is thought to have a potential constricting effect on the blood vessels. As a result, patients with heart disease and high blood pressure are advised not to take it.
Telcagepant does not appear to have the same vasoconstricting (blood vessel narrowing) properties, but heart patients were excluded from the trial. The study was conducted among 1,380 patients in 81 hospitals in the US and Europe, led by Tony Ho of Merck Research Laboratories, Philadelphia.
- 1 Ninety gaffes in ninety years
- 2 Spotify: 1 million plays, £108 return
- 3 Apple admits it has a human rights problem
- 4 Rothschild loses libel case, and reveals secret world of money and politics
- 5 Rangers future could be bright says administrator
- 6 MP faces charges over Nazi stag night
- 7 Six Grammys, five years off: Adele puts love before career
- 8 No secularism please, we're British
- 9 Mark Steel: If religion is 'marginal', I'm the Pope
- 10 Lightning kills an entire football team
Free trial of new Independent iPad app
Get your daily dose of the best of British journalism, sponsored by American Airlines
Amazing restaurant offers
Three glasses of free champagne and a special menu at 46 top London restaurants.
Latest Independent competitions
Win anything from gadgets to five-star holidays on our competitions and offers page.
Commercial thought leaders
Watch the best in the business world give their insights into the world of business.
Career Services
Day In a Page
How an abortion divided America
Did they all live happily ever after? That's up to you...




Comments